Uğur Şahin, CEO of Biontech, which developed the coronavirus vaccine, made statements after the FDA approved the third dose of vaccine. Şahin said that the third dose of vaccine gave a strong immunity against the variants.
Kovid-19 vaccines, which prevent cases and deaths in the pandemic and give the whole world a sigh of relief, continue to be applied worldwide.
The U.S. Food and Drug Administration (FDA) announced that it has approved the third dose of the Pfizer-BioNTech vaccine for people over 65 years of age, with chronic diseases and those working in risky jobs.
The announcement recommended that the third dose of the vaccine be administered six months after the second dose. Following this step, new statements came from Uğur Şahin, CEO and co-founder of BioNTech company, which developed a vaccine against Kovid-19 with mRNA technology.
3rd dose decision for BioNTech/Pfizer vaccine Remarkable 3rd dose decision for BioNTech/Pfizer vaccineHealth
Underlining that in the light of the clinical data obtained, the third dose of vaccine provides a strong immunity against the variants in the ‘concerning’ category, Şahin used the following statements;
The emergency use approval granted will meet the needs of public health. We will continue to monitor the coronavirus and be prepared for potential variants.”
Stating that they shared the data of the third dose of vaccine with the supervisory institutions of the countries, Şahin said, “We are working to make our vaccine accessible globally.”
Speaking to the Kölner Stadt-Anzeiger newspaper last week, Şahin reiterated his call for the third dose of booster vaccines to be given to adults who have received two doses of vaccine.
In his statement on the subject, Şahin said, “It would be very reasonable for people with weakened immune defense to get a third dose of vaccine.”